HRP20190825T1 - Regulacija genske ekspresije posredovana nukleazama - Google Patents
Regulacija genske ekspresije posredovana nukleazama Download PDFInfo
- Publication number
- HRP20190825T1 HRP20190825T1 HRP20190825TT HRP20190825T HRP20190825T1 HR P20190825 T1 HRP20190825 T1 HR P20190825T1 HR P20190825T T HRP20190825T T HR P20190825TT HR P20190825 T HRP20190825 T HR P20190825T HR P20190825 T1 HRP20190825 T1 HR P20190825T1
- Authority
- HR
- Croatia
- Prior art keywords
- cell
- protein
- tale
- zinc finger
- nuclease
- Prior art date
Links
- 101710163270 Nuclease Proteins 0.000 title claims 10
- 230000001404 mediated effect Effects 0.000 title 1
- 230000014493 regulation of gene expression Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 17
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 108060003196 globin Proteins 0.000 claims 9
- 230000014509 gene expression Effects 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 101710185494 Zinc finger protein Proteins 0.000 claims 5
- 102100023597 Zinc finger protein 816 Human genes 0.000 claims 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 4
- 210000003743 erythrocyte Anatomy 0.000 claims 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000011701 zinc Substances 0.000 claims 4
- 229910052725 zinc Inorganic materials 0.000 claims 4
- 238000010362 genome editing Methods 0.000 claims 3
- 102000018146 globin Human genes 0.000 claims 3
- 208000034737 hemoglobinopathy Diseases 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims 2
- 108700019146 Transgenes Proteins 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 230000010354 integration Effects 0.000 claims 2
- 230000032965 negative regulation of cell volume Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 102100022976 B-cell lymphoma/leukemia 11A Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 1
- 101000903703 Homo sapiens B-cell lymphoma/leukemia 11A Proteins 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 208000005980 beta thalassemia Diseases 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 108010038853 gamma-Globins Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (15)
1. Genetski modificirana stanica koja sadrži genomsku modifikaciju nastalu djelovanjem nukleaze sa cinkanim prstićima (ZFN) ili nukleaze sa efektorskom domenom tipa TAL (TALEN), pri čemu je genomska modifikacija unutar bilo koje od nukleaznih cilјnih sekvenci u SEQ ID NO: 4-80, 143-184, 232-251 i 276 endogene sekvence pojačivača BCL11a i, dalje, pri čemu je genomska modifikacija tipa insercije i/ili delecije.
2. Genetski modificirana stanica prema patentnom zahtjevu 1, pri čemu je stanica matična stanica, opcionalno pri čemu je matična stanica hematopoetska matična stanica kao što je CD34+ hematopoetska matična stanica.
3. Genetski modificirana diferencirana stanica koja potječe od matične stanice prema patentnom zahtjevu 2, opcionalno pri čemu je stanica crvena krvna stanica (RBC).
4. Genetski modificirana stanica prema bilo kojem od patentnih zahtjeva od 1 do 3, gdje:
(a) nukleaza se uvodi u stanicu kao polinukleotid; i/ili
(b) insercija obuhvaća integraciju donorskog polinukleotida koji kodira transgen, opcionalno gdje:
(i) ZFN obuhvaća protein sa strukturama cinkanih prstića, protein sa cinkanim prstićima koji se sastoji od 4, 5 ili 6 domena cinkanih prstića koji sadrže područje prepoznavanja heliksa i, dalјe, gdje protein sa cinkanim prstićima sadrži područja prepoznavanja heliksa po redoslijedu prikazanom u jednom redu Tabele 3 ili Tabele 6; ili
(ii) TALEN obuhvaća TALE protein, a TALE protein se sastoji od mnoštva TALE ponovaka, gdje svaki ponovak sadrži hipervarijabilno direzidualno područje (RVD), pri čemu su RVD ovih TALE ponovaka prikazani u jednom redu Tabele 1, Tabele 2 ili Tabele 4.
5. Farmaceutski sastav koji sadrži genetski modificiranu stanicu prema bilo kojem od patentnih zahtjeva od 1 do 4.
6. Protein koji vezuje DNK i sadrži protein sa cinkanim prstićima ili efektorski protein tipa TALE (TALE), gdje se
(i) protein sa cinkanim prstićima sastoji od 4, 5 ili 6 domena sa cinkanim prstićima koji sadrže područje prepoznavanja heliksa, pri čemu proteini sa cinkanim prstićima sadrže područja prepoznavanja heliksa po redoslijedu prikazanom u jednom redu Tabele 3 ili Tabele 6; i
(ii) TALE protein se sastoji od mnoštva TALE ponovaka, gdje svaki ponovak sadrži hipervarijabilno direzidualno područje (RVD), pri čemu su RVD ovih TALE ponovaka prikazani u jednom redu Tabele 1, Tabele 2 ili Tabele 4.
7. Nukleaza koja sadrži protein sa cinkanim prstićima ili TALE protein prema patentnom zahtjevu 6 i domen isjecanja ili poludomen isjecanja koji je divljeg tipa ili genetski konstruiran.
8. Polinukleotid koji kodira jedan ili više proteina prema patentnom zahtjevu 6 ili nukleazu prema patentnom zahtjevu 7.
9. Izolirana stanica koja sadrži jedan ili više proteina prema patentnom zahtjevu 6 ili patentnom zahtjevu 7 ili jedan ili više polinukleotida prema patentnom zahtjevu 8, opcionalno gdje je stanica hematopoetska matična stanica.
10. Komplet koji sadrži najmanje jedno od: i) polinukleotida koji kodira protein prema patentnom zahtjevu 6 ili patentnom zahtjevu 7 ili ii) protein prema patentnom zahtjevu 6 ili patentnom zahtjevu 7.
11. Postupak izmjene ekspresije globinskog gena u stanici in vitro, postupak koji obuhvaća:
uvođenje, u stanicu, jednog ili više polinukleotida prema patentnom zahtjevu 8, pod uvjetima koji omogućavaju da se eksprimira jedan ili više proteina i da se izmjeni ekspresija globinskog gena, opcionalno gdje je ekspresija globinskog gena povećana i/ili globinski gen je gen za gama globin ili beta globin.
12. Postupak prema patentnom zahtjevu 11, koji dalje uključuje integraciju donorske sekvence u genom stanice, opcionalno gdje:
(a) donorska sekvenca se uvodi u stanicu upotrebom virusnog vektora, kao oligonukleotid ili u okviru plazmida;
(b) stanica je izabrana iz grupe koju čine prekursorska stanica crvenih krvnih stanica (RBC) i hematopoetska matična stanica; i/ili
(c) donorska sekvenca sadrži transgen pod kontrolom endogenog ili egzogenog promotora.
13. Farmaceutski sastav prema patentnom zahtjevu 5, za upotrebu u postupku liječenja ili prevencije hemoglobinopatije kod pacijenta kome je potrebno povećanje ekspresije globinskog gena, postupka koji se sastoji od primjene farmaceutskog sastava pacijentu, u količini dovolјnoj da se poveća ekspresija globinskog gena kod pacijenta, opcionalno gdje je hemoglobinopatija talasemija ili anemija srpastih stanica kao što je β-talasemija.
14. Postupak prema patentnom zahtjevu 11 ili farmaceutski sastav za upotrebu prema patentnom zahtjevu 13, gdje ekspresija globinskog gena označava nivo proizvedene globinske iRNK ili globinskog proteina.
15. Jedna ili više nukleaza prema patentnom zahtjevu 7 ili nukleinska kiselina koja kodira jednu ili više nukleaza koje se vezuju za cilјnu sekvencu u okviru bilo koje od SEQ ID NO:4-80, 143-184, 232-251 i 276, za upotrebu u liječenju ili prevenciji hemoglobinopatije, pri čemu nukleaza cilјano djeluje na sekvencu pojačivača BCL11A u stanici i pri čemu su jedna ili više nukleaza tipa ZFN ili TALEN.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361903823P | 2013-11-13 | 2013-11-13 | |
US201462042075P | 2014-08-26 | 2014-08-26 | |
PCT/US2014/065473 WO2015073683A2 (en) | 2013-11-13 | 2014-11-13 | Nuclease-mediated regulation of gene expression |
EP14861930.7A EP3068881B1 (en) | 2013-11-13 | 2014-11-13 | Nuclease-mediated regulation of gene expression |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20190825T1 true HRP20190825T1 (hr) | 2019-06-28 |
Family
ID=53043976
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211706TT HRP20211706T1 (hr) | 2013-11-13 | 2014-11-13 | Nukleazom posredovana regulacija ekspresije gena |
HRP20190825TT HRP20190825T1 (hr) | 2013-11-13 | 2019-05-02 | Regulacija genske ekspresije posredovana nukleazama |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211706TT HRP20211706T1 (hr) | 2013-11-13 | 2014-11-13 | Nukleazom posredovana regulacija ekspresije gena |
Country Status (13)
Country | Link |
---|---|
US (2) | US11021696B2 (hr) |
EP (3) | EP3960856A1 (hr) |
CY (1) | CY1121630T1 (hr) |
DK (2) | DK3068881T3 (hr) |
ES (2) | ES2721936T3 (hr) |
HR (2) | HRP20211706T1 (hr) |
HU (2) | HUE044540T2 (hr) |
LT (2) | LT3492593T (hr) |
PL (2) | PL3492593T3 (hr) |
PT (2) | PT3492593T (hr) |
RS (2) | RS58671B1 (hr) |
SI (2) | SI3068881T1 (hr) |
WO (1) | WO2015073683A2 (hr) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2734621B1 (en) | 2011-07-22 | 2019-09-04 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
DK3502240T3 (da) | 2012-11-27 | 2021-08-09 | Childrens Medical Ct Corp | Målretning af distale bcl11a-reguleringselementer til føtal hæmoglobinreinduktion |
US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
PT3066201T (pt) | 2013-11-07 | 2018-06-04 | Massachusetts Inst Technology | Métodos e composições relacionadas com crispr com arng reguladores |
US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
ES2744186T3 (es) | 2014-04-25 | 2020-02-24 | Childrens Medical Center | Composiciones y métodos para tratar las hemoglobinopatías |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
JP7288302B2 (ja) * | 2015-05-08 | 2023-06-07 | ザ チルドレンズ メディカル センター コーポレーション | 胎児型ヘモグロビン再誘導のための、bcl11aエンハンサー機能性領域を標的とする方法 |
MX2017014446A (es) | 2015-05-12 | 2018-06-13 | Sangamo Therapeutics Inc | Regulacion de expresion genica mediada por nucleasa. |
US9957501B2 (en) | 2015-06-18 | 2018-05-01 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
JP7067793B2 (ja) | 2015-10-23 | 2022-05-16 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 核酸塩基編集因子およびその使用 |
EP3389677A4 (en) | 2015-12-18 | 2019-05-22 | Sangamo Therapeutics, Inc. | TARGETED DESTRUCTION OF THE T-CELL RECEPTOR |
EA201891212A1 (ru) | 2015-12-18 | 2019-01-31 | Сангамо Терапьютикс, Инк. | Адресная дезорганизация клеточного рецептора гкгс |
EA201891532A1 (ru) * | 2015-12-28 | 2019-01-31 | Новартис Аг | Композиции и способы лечения гемоглобинопатий |
US11427837B2 (en) | 2016-01-12 | 2022-08-30 | The Regents Of The University Of California | Compositions and methods for enhanced genome editing |
WO2017143071A1 (en) * | 2016-02-18 | 2017-08-24 | The Regents Of The University Of California | Methods and compositions for gene editing in stem cells |
JP7231935B2 (ja) | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
WO2018039448A1 (en) | 2016-08-24 | 2018-03-01 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
BR112019003100A2 (pt) | 2016-08-24 | 2019-07-09 | Sangamo Therapeutics Inc | regulação da expressão gênica usando nucleases manipuladas |
EP3509645A4 (en) * | 2016-09-07 | 2020-06-17 | Sangamo Therapeutics, Inc. | MODULATION OF LIVER GENES |
KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
EP3592777A1 (en) | 2017-03-10 | 2020-01-15 | President and Fellows of Harvard College | Cytosine to guanine base editor |
EP3596217A1 (en) | 2017-03-14 | 2020-01-22 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
AU2018237159A1 (en) | 2017-03-22 | 2019-09-05 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
KR20190130613A (ko) | 2017-03-23 | 2019-11-22 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
US11261441B2 (en) | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
JP2020518245A (ja) | 2017-05-03 | 2020-06-25 | サンガモ セラピューティクス, インコーポレイテッド | 嚢胞性線維症膜貫通コンダクタンス制御因子(cftr)遺伝子の改変のための方法および組成物 |
WO2018209158A2 (en) * | 2017-05-10 | 2018-11-15 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
US11788087B2 (en) | 2017-05-25 | 2023-10-17 | The Children's Medical Center Corporation | BCL11A guide delivery |
US11512287B2 (en) | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
WO2018237291A2 (en) * | 2017-06-22 | 2018-12-27 | The Children's Medical Center Corporation | CENTERS OF ERYTHROID DIFFERENTIATION SIGNALING |
US20200140896A1 (en) | 2017-06-30 | 2020-05-07 | Novartis Ag | Methods for the treatment of disease with gene editing systems |
JP2020534795A (ja) | 2017-07-28 | 2020-12-03 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物 |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
WO2019079347A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | USES OF BASIC EDITORS ADENOSINE |
CN109722414A (zh) * | 2017-10-27 | 2019-05-07 | 博雅辑因(北京)生物科技有限公司 | 一种高效制备成熟红细胞的方法以及用于制备成熟红细胞的培养基 |
WO2019150196A1 (en) * | 2018-02-05 | 2019-08-08 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
CN110678553B (zh) * | 2018-08-21 | 2023-08-11 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 在哺乳动物干细胞中进行基因组编辑的方法 |
EP3942040A1 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
BR112021019448A2 (pt) | 2019-04-02 | 2021-11-30 | Sangamo Therapeutics Inc | Métodos para o tratamento de beta-talassemia |
AU2020279370A1 (en) | 2019-05-21 | 2021-12-16 | Sangamo Therapeutics, Inc. | Controlled transgene expression in regulatory T cells |
EP4010004A4 (en) * | 2019-08-07 | 2023-09-13 | Altius Institute For Biomedical Sciences | COMPOSITIONS AND METHODS OF GENE EXPRESSION MODULATION |
WO2021226558A1 (en) | 2020-05-08 | 2021-11-11 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
EP4288551A1 (en) * | 2021-02-02 | 2023-12-13 | Limagrain Europe | Linkage of a distal promoter to a gene of interest by gene editing to modify gene expression |
CN114015674A (zh) | 2021-11-02 | 2022-02-08 | 辉二(上海)生物科技有限公司 | 新型CRISPR-Cas12i系统 |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US5422251A (en) | 1986-11-26 | 1995-06-06 | Princeton University | Triple-stranded nucleic acids |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
ATE310812T1 (de) | 1994-01-18 | 2005-12-15 | Scripps Research Inst | Derivate von zinkfingerproteinen und methoden |
EP0752005B1 (en) | 1994-03-23 | 2008-10-08 | Ohio University | Compacted nucleic acids and their delivery to cells |
ATE386131T1 (de) | 1994-04-13 | 2008-03-15 | Univ Rockefeller | Aav-vermittelte überbringung von dna in zellen des nervensystems |
US5585245A (en) | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
JP4118327B2 (ja) | 1994-08-20 | 2008-07-16 | ゲンダック・リミテッド | Dna認識のための結合タンパク質におけるまたはそれに関連する改良 |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6240461B1 (en) | 1997-09-25 | 2001-05-29 | Cisco Technology, Inc. | Methods and apparatus for caching network data traffic |
US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
US6479626B1 (en) | 1998-03-02 | 2002-11-12 | Massachusetts Institute Of Technology | Poly zinc finger proteins with improved linkers |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
WO2000046386A2 (en) | 1999-02-03 | 2000-08-10 | The Children's Medical Center Corporation | Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
US20030104526A1 (en) | 1999-03-24 | 2003-06-05 | Qiang Liu | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
WO2001040798A2 (en) | 1999-12-06 | 2001-06-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
EP1254369B1 (en) | 2000-02-08 | 2010-10-06 | Sangamo BioSciences, Inc. | Cells for drug discovery |
US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
WO2002077277A2 (en) | 2001-03-26 | 2002-10-03 | Council Of Scientific And Industrial Research | Dna markers for assessing seed purity and a method of using dna sequences for assessing seed purity |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
JP2005500061A (ja) | 2001-08-20 | 2005-01-06 | ザ スクリップス リサーチ インスティテュート | Cnnについての亜鉛フィンガー結合ドメイン |
US6998118B2 (en) | 2001-12-21 | 2006-02-14 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery for neuronal protection |
US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
ATE347593T1 (de) | 2002-01-23 | 2006-12-15 | Univ Utah Res Found | Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen |
EP2368982A3 (en) | 2002-03-21 | 2011-10-12 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
WO2004037977A2 (en) | 2002-09-05 | 2004-05-06 | California Institute Of Thechnology | Use of chimeric nucleases to stimulate gene targeting |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
DK2927318T3 (da) * | 2003-08-08 | 2020-08-03 | Sangamo Therapeutics Inc | Fremgangsmåde og sammensætninger til målrettet spaltning og rekombination |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
US20060239966A1 (en) | 2003-10-20 | 2006-10-26 | Tornoee Jens | In vivo gene therapy of parkinson's disease |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
AU2005232665B2 (en) | 2004-04-08 | 2010-05-13 | Sangamo Therapeutics, Inc. | Methods and compositions for treating neuropathic and neurodegenerative conditions |
JP2008506359A (ja) | 2004-04-08 | 2008-03-06 | サンガモ バイオサイエンシズ インコーポレイテッド | ジンクフィンガータンパク質による神経因性疼痛の処置 |
EP1789095A2 (en) | 2004-09-16 | 2007-05-30 | Sangamo Biosciences Inc. | Compositions and methods for protein production |
EP1877583A2 (en) | 2005-05-05 | 2008-01-16 | Arizona Board of Regents on behalf of the Unversity of Arizona | Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences |
SG10201508995QA (en) | 2005-07-26 | 2015-11-27 | Sangamo Biosciences Inc | Targeted integration and expression of exogenous nucleic acid sequences |
DK1945762T3 (da) | 2005-10-18 | 2013-07-29 | Prec Biosciences | Rationelt konstruerede meganucleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet |
JP5551432B2 (ja) | 2006-05-25 | 2014-07-16 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 遺伝子不活性化のための方法と組成物 |
CA2651494C (en) | 2006-05-25 | 2015-09-29 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
US7837668B2 (en) | 2006-10-10 | 2010-11-23 | Ceregene, Inc. | Needle assembly for use in delivering precise dosages of proteinaceous pharmaceutical compositions and methods for use of same |
KR101613624B1 (ko) * | 2006-12-14 | 2016-04-29 | 다우 아그로사이언시즈 엘엘씨 | 최적화된 비-정규 아연 손가락 단백질 |
ATE489465T1 (de) | 2007-04-26 | 2010-12-15 | Sangamo Biosciences Inc | Gezielte integration in die ppp1r12c-position |
US8585526B2 (en) | 2007-06-18 | 2013-11-19 | American Axle & Manufacturing, Inc. | Vehicle driveline component having heat sink for increased heat rejection capabilities |
PL2167523T3 (pl) | 2007-06-19 | 2014-12-31 | Univ Louisiana State | Synteza i zastosowanie anty-odwrotnych tiofosforanowych analogów kapu matrycowego RNA |
WO2009042163A2 (en) | 2007-09-27 | 2009-04-02 | Sangamo Biosciences, Inc. | Rapid in vivo identification of biologically active nucleases |
EP2597155B1 (en) | 2007-10-25 | 2016-11-23 | Sangamo BioSciences, Inc. | Methods and compositions for targeted integration |
DE102007056956B4 (de) | 2007-11-27 | 2009-10-29 | Moosbauer, Peter, Dipl.-Ing.(FH) | Schaltung zur Regelung der Stromversorgung eines Verbrauchers und Verfahren zum Betrieb einer Schaltung |
CA2725773C (en) | 2008-05-28 | 2017-12-05 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
KR20160015400A (ko) | 2008-08-22 | 2016-02-12 | 상가모 바이오사이언스 인코포레이티드 | 표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물 |
MX345116B (es) | 2008-09-15 | 2017-01-17 | Children's Medical Center Corp | Modulacion de bcl11a para tratamiento de hemoglobinopatias. |
WO2010065123A1 (en) | 2008-12-04 | 2010-06-10 | Sangamo Biosciences, Inc. | Genome editing in rats using zinc-finger nucleases |
EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
EP2419511B1 (en) | 2009-04-09 | 2018-01-17 | Sangamo Therapeutics, Inc. | Targeted integration into stem cells |
WO2010147621A1 (en) * | 2009-06-16 | 2010-12-23 | The Trustees Of Columbia University In The City Of New York | Methods for ameliorating adverse effects associated with transfusion of aged red blood cells |
KR20120097484A (ko) | 2009-07-31 | 2012-09-04 | 에트리스 게엠베하 | 단백질 발현을 위한 비변형된 뉴클레오티드 및 변형된 뉴클레오티드의 조합을 가진 rna |
PT2534173T (pt) | 2010-02-08 | 2019-10-31 | Sangamo Therapeutics Inc | Semidomínios de clivagem manipulados |
JP2013518602A (ja) | 2010-02-09 | 2013-05-23 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 部分的に一本鎖のドナー分子による標的化ゲノム改変 |
CA2796600C (en) | 2010-04-26 | 2019-08-13 | Sangamo Biosciences, Inc. | Genome editing of a rosa locus using zinc-finger nucleases |
LT2566972T (lt) | 2010-05-03 | 2020-03-10 | Sangamo Therapeutics, Inc. | Kompozicijos, skirtos cinko pirštu modulių susiejimui |
EP3156062A1 (en) | 2010-05-17 | 2017-04-19 | Sangamo BioSciences, Inc. | Novel dna-binding proteins and uses thereof |
US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
AU2012222144B2 (en) * | 2011-02-25 | 2017-04-27 | Recombinetics, Inc. | Genetically modified animals and methods for making the same |
US9394545B2 (en) | 2011-09-21 | 2016-07-19 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
EP2766041B1 (en) * | 2011-10-12 | 2018-12-05 | Children's Medical Center Corporation | Combinatorial compositions and methods of treating hemoglobinopathies |
JP6188703B2 (ja) * | 2011-10-27 | 2017-08-30 | サンガモ セラピューティクス, インコーポレイテッド | Hprt遺伝子座を修飾するための方法および組成物 |
SG10201606959PA (en) | 2012-02-24 | 2016-09-29 | Hutchinson Fred Cancer Res | Compositions and methods for the treatment of hemoglobinopathies |
BR112014027813A2 (pt) | 2012-05-07 | 2017-08-08 | Dow Agrosciences Llc | métodos e composições para integração de transgenes direcionada mediada por nuclease |
LT2890780T (lt) | 2012-08-29 | 2020-11-10 | Sangamo Therapeutics, Inc. | Būdai ir kompozicijos, skirti genetinės būklės gydymui |
DK3502240T3 (da) * | 2012-11-27 | 2021-08-09 | Childrens Medical Ct Corp | Målretning af distale bcl11a-reguleringselementer til føtal hæmoglobinreinduktion |
CN105683376A (zh) | 2013-05-15 | 2016-06-15 | 桑格摩生物科学股份有限公司 | 用于治疗遗传病状的方法和组合物 |
EP3988654A1 (en) | 2013-08-28 | 2022-04-27 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
MX2017014446A (es) * | 2015-05-12 | 2018-06-13 | Sangamo Therapeutics Inc | Regulacion de expresion genica mediada por nucleasa. |
-
2014
- 2014-11-13 WO PCT/US2014/065473 patent/WO2015073683A2/en active Application Filing
- 2014-11-13 PT PT182147116T patent/PT3492593T/pt unknown
- 2014-11-13 PL PL18214711T patent/PL3492593T3/pl unknown
- 2014-11-13 PL PL14861930T patent/PL3068881T3/pl unknown
- 2014-11-13 ES ES14861930T patent/ES2721936T3/es active Active
- 2014-11-13 HR HRP20211706TT patent/HRP20211706T1/hr unknown
- 2014-11-13 HU HUE14861930 patent/HUE044540T2/hu unknown
- 2014-11-13 EP EP21187166.0A patent/EP3960856A1/en active Pending
- 2014-11-13 DK DK14861930.7T patent/DK3068881T3/en active
- 2014-11-13 SI SI201431119T patent/SI3068881T1/sl unknown
- 2014-11-13 ES ES18214711T patent/ES2895069T3/es active Active
- 2014-11-13 LT LTEP18214711.6T patent/LT3492593T/lt unknown
- 2014-11-13 EP EP14861930.7A patent/EP3068881B1/en active Active
- 2014-11-13 SI SI201431907T patent/SI3492593T1/sl unknown
- 2014-11-13 RS RS20190520A patent/RS58671B1/sr unknown
- 2014-11-13 RS RS20211358A patent/RS62559B1/sr unknown
- 2014-11-13 US US14/540,729 patent/US11021696B2/en active Active
- 2014-11-13 PT PT14861930T patent/PT3068881T/pt unknown
- 2014-11-13 HU HUE18214711A patent/HUE056436T2/hu unknown
- 2014-11-13 DK DK18214711.6T patent/DK3492593T3/da active
- 2014-11-13 LT LTEP14861930.7T patent/LT3068881T/lt unknown
- 2014-11-13 EP EP18214711.6A patent/EP3492593B1/en active Active
-
2019
- 2019-05-02 HR HRP20190825TT patent/HRP20190825T1/hr unknown
- 2019-05-15 CY CY20191100521T patent/CY1121630T1/el unknown
-
2021
- 2021-04-26 US US17/239,780 patent/US20210348143A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
DK3068881T3 (en) | 2019-04-15 |
EP3960856A1 (en) | 2022-03-02 |
PL3068881T3 (pl) | 2019-08-30 |
EP3068881A2 (en) | 2016-09-21 |
EP3492593B1 (en) | 2021-08-18 |
HUE044540T2 (hu) | 2019-10-28 |
RS58671B1 (sr) | 2019-06-28 |
WO2015073683A2 (en) | 2015-05-21 |
HRP20211706T1 (hr) | 2022-02-04 |
US20210348143A1 (en) | 2021-11-11 |
HUE056436T2 (hu) | 2022-02-28 |
LT3492593T (lt) | 2021-11-25 |
US20150132269A1 (en) | 2015-05-14 |
EP3068881B1 (en) | 2019-02-27 |
SI3492593T1 (sl) | 2022-03-31 |
DK3492593T3 (da) | 2021-11-08 |
EP3492593A1 (en) | 2019-06-05 |
ES2895069T3 (es) | 2022-02-17 |
PL3492593T3 (pl) | 2022-04-19 |
ES2721936T3 (es) | 2019-08-06 |
WO2015073683A3 (en) | 2015-07-09 |
PT3068881T (pt) | 2019-05-31 |
LT3068881T (lt) | 2019-08-12 |
SI3068881T1 (sl) | 2019-05-31 |
RS62559B1 (sr) | 2021-12-31 |
EP3068881A4 (en) | 2017-04-19 |
CY1121630T1 (el) | 2020-07-31 |
PT3492593T (pt) | 2021-10-18 |
US11021696B2 (en) | 2021-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20190825T1 (hr) | Regulacija genske ekspresije posredovana nukleazama | |
HRP20201443T1 (hr) | Postupci i pripravci za liječenje genetskog stanja | |
HRP20201038T1 (hr) | Postupci i pripravci za liječenje beta talasemije | |
US20240035049A1 (en) | Methods and compositions for modulating a genome | |
ES2962434T3 (es) | Procedimientos y composiciones para editar ARN | |
JP2017532955A5 (hr) | ||
JP2019508051A5 (hr) | ||
JP2015533786A5 (hr) | ||
WO2017053431A3 (en) | Allele selective gene editing and uses thereof | |
RU2017124909A (ru) | Способы и композиции для нацеленной генетической модификации посредством одноэтапного множественного нацеливания | |
JP2017538428A5 (hr) | ||
WO2017181107A2 (en) | Modified cpf1 mrna, modified guide rna, and uses thereof | |
EP3443085A1 (en) | Genome editing of human neural stem cells using nucleases | |
CA3136735A1 (en) | Methods and compositions for editing rnas | |
HRP20211468T1 (hr) | Postupci i pripravci za nukleazno posredovani inženjering genoma i ispravak u krvotvornim matičnim stanicama | |
JP2015518710A5 (hr) | ||
JP2019525759A5 (hr) | ||
RU2016126989A (ru) | Способы и композиции для направленной модификации генома | |
WO2015148860A1 (en) | Crispr/cas-related methods and compositions for treating beta-thalassemia | |
JP2015518712A5 (hr) | ||
JP2009219504A5 (hr) | ||
EP3596217A1 (en) | Systems and methods for the treatment of hemoglobinopathies | |
RU2015128102A (ru) | Компоненты системы crispr-cas, способы и композиции для манипуляции с последовательностями | |
RU2022103641A (ru) | Искусственная модификация генома для регуляции экспрессии гена | |
Takahashi et al. | Widespread genome transcription: new possibilities for RNA therapies |